Research continues beyond B-cell lymphoma, targeting other hematological malignancies with promising developments utilizing markers like CD33, CD45, and CD66, in addition to alpha emitters such as Bi-212 and Ac-225, which show better efficacy than beta emitters in cancers like acute myeloid leukemia (AML) [52]. Here, PTPRC is linked to acute myeloid leukemia.